Juan Enrique Schwarze
Research Subjects
Juan Enrique Schwarze has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Carolina Musri
Unit of Reproductive Medicine Clínica Las Condes, Santiago, Chile
6 shared publications- Fernando Zegers-Hochschild
Program of Ethics and Public Policies in Human Reproduction, Faculty de Medicine, University Diego Portales, Santiago, Chile
5 shared publications Javier Crosby
Unit of Reproductive Medicine Clínica Las Condes, Lo Fontecilla 441, Santiago, Chile; Latin American Network of Assisted Reproduction (REDLARA), Plaza Independencia 811 Montevideo, Uruguay
4 shared publications- Javier A. Crosby
Unit of Reproductive Medicine, Clínica las Condes, Lo Fontecilla 4412, Santiago, Chile
3 shared publications Maria Do Carmo Borges de Souza
Fertipraxis- Centro de Reprodução Humana, Av. das Américas, 4.666 grupos 312/313, Rio de Janeiro, Brasil
3 shared publicationsMaria Teresa Urbina
Latin American Network of Assisted Reproduction (REDLARA), Montevideo, Uruguay
3 shared publications
Latest Publications
- Open Access
- 23 February 2026
- Published by S. Karger AG in Gynecologic and Obstetric Investigation
- p. 1-14
Comparative Effectiveness of Recombinant Human Follicle-Stimulating Hormone:Recombinant Human Luteinizing Hormone in a 2:1 Ratio versus Highly Purified Human Menopausal Gonadotropin Alone in Ovarian Stimulation for Medically Assisted Reproduction Treatment Using in vitro Fertilization/Intracytoplasmic Sperm Injection: A Systematic Review and Meta-Analysis
Introduction: Investigation of the number of oocytes recovered from different ovarian stimulation (OS) protocols is essential, as oocyte number is positively associated with the number of good-quality embryos obtained; however, there are few data comparing the number of oocytes retrieved following OS with recombinant or urinary gonadotropins. Methods: A systematic review and meta-analysis of published evidence was performed to compare the number of oocytes retrieved with recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) in a 2:1 ratio versus highly purified human menopausal gonadotropin (HP-hMG) alone from day 1 of OS. The literature search was conducted according to PRISMA guidelines (https://www.prisma-statement.org/) using Medline, EMBASE, Biosis, SciSearch, and TOXCENTER on STN. Studies were included if they reported on r-hFSH:r-hLH in a 2:1 ratio versus HP-hMG alone, both administered from day 1 of OS, and the results for the number of oocytes retrieved were presented for both interventions. Data were extracted from the full articles independently by two reviewers (J.-E.S. and B.H.). Results were analyzed using a random-effects meta-analysis model. Any potential risk of bias was assessed using the ROBINS-I tool. Secondary outcomes were the number of mature (MII) oocytes, clinical pregnancy rate, ongoing pregnancy rate, and live birth rate. Results: Six studies were included in the meta-analysis (5,287 cycles): four non-interventional studies, one non-interventional cross-over study, and one randomized controlled trial. The number of oocytes per cycle was significantly higher in women treated with r-hFSH:r-hLH 2:1 compared with those treated with HP-hMG alone (mean difference 1.43, 95% confidence interval [CI]: 0.18–2.69; p = 0.025). Clinical pregnancy rate per started cycle was significantly higher with r-hFSH:r-hLH 2:1 compared with HP-hMG (rate ratio 1.18, 95% CI: 1.06–1.33; p = 0.004; five studies). There were insufficient data to draw any firm conclusions on the other secondary outcomes. Conclusions: The higher number of oocytes retrieved with r-hFSH:r-hLH is a pertinent finding, owing to the well-established positive association between oocyte number and reproductive outcomes. Although we report a higher clinical pregnancy rate for r-hFSH:r-hLH 2:1, limited data prevented us from drawing firm conclusions regarding live birth outcomes.
- 23 February 2026
- Published by S. Karger AG in Gynecologic and Obstetric Investigation
- p. 1-14
Open AccessComparative Effectiveness of Recombinant Human Follicle-Stimulating Hormone:Recombinant Human Luteinizing Hormone in a 2:1 Ratio versus Highly Purified Human Menopausal Gonadotropin Alone in Ovarian Stimulation for Medically Assisted Reproduction Treatment Using in vitro Fertilization/Intracytoplasmic Sperm Injection: A Systematic Review and Meta-Analysis
Introduction: Investigation of the number of oocytes recovered from different ovarian stimulation (OS) protocols is essential, as oocyte number is positively associated with the number of good-quality embryos obtained; however, there are few data comparing the number of oocytes retrieved following OS with recombinant or urinary gonadotropins. Methods: A systematic review and meta-analysis of published evidence was performed to compare the number of oocytes retrieved with recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) in a 2:1 ratio versus highly purified human menopausal gonadotropin (HP-hMG) alone from day 1 of OS. The literature search was conducted according to PRISMA guidelines (https://www.prisma-statement.org/) using Medline, EMBASE, Biosis, SciSearch, and TOXCENTER on STN. Studies were included if they reported on r-hFSH:r-hLH in a 2:1 ratio versus HP-hMG alone, both administered from day 1 of OS, and the results for the number of oocytes retrieved were presented for both interventions. Data were extracted from the full articles independently by two reviewers (J.-E.S. and B.H.). Results were analyzed using a random-effects meta-analysis model. Any potential risk of bias was assessed using the ROBINS-I tool. Secondary outcomes were the number of mature (MII) oocytes, clinical pregnancy rate, ongoing pregnancy rate, and live birth rate. Results: Six studies were included in the meta-analysis (5,287 cycles): four non-interventional studies, one non-interventional cross-over study, and one randomized controlled trial. The number of oocytes per cycle was significantly higher in women treated with r-hFSH:r-hLH 2:1 compared with those treated with HP-hMG alone (mean difference 1.43, 95% confidence interval [CI]: 0.18–2.69; p = 0.025). Clinical pregnancy rate per started cycle was significantly higher with r-hFSH:r-hLH 2:1 compared with HP-hMG (rate ratio 1.18, 95% CI: 1.06–1.33; p = 0.004; five studies). There were insufficient data to draw any firm conclusions on the other secondary outcomes. Conclusions: The higher number of oocytes retrieved with r-hFSH:r-hLH is a pertinent finding, owing to the well-established positive association between oocyte number and reproductive outcomes. Although we report a higher clinical pregnancy rate for r-hFSH:r-hLH 2:1, limited data prevented us from drawing firm conclusions regarding live birth outcomes.
- Open Access
- 25 July 2023
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 89, 102395
Withdrawal notice to: ‘Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35–40 years: A German database study’ [YBEOG 89C (2023) 102350]
- 25 July 2023
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 89, 102395
Open AccessWithdrawal notice to: ‘Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35–40 years: A German database study’ [YBEOG 89C (2023) 102350]
- Open Access
- 1 January 2019
- Published by GN1 Sistemas e Publicacoes Ltd. in JBRA Assisted Reproduction
- Vol. 23 (2) , 143-153
Assisted Reproductive Techniques in Latin America: The Latin American Registry, 2015
What was the utilization, effectiveness and safety of assisted reproductive technologies (ART) performed in Latin American countries during 2015, and what were the regional trends? Retrospective collection of multinational data on assisted reproduction techniques (IVF and intracytoplasmic sperm injection [ICSI], frozen embryo transfer, oocyte donation, preimplantation genetic testing and fertility preservation), from 175 institutions in 15 Latin American countries. In total, 41.25% of IVF/ICSI cycles were performed in women aged 35-39 years, and 28.35% in women aged ≥40 years. After removing freeze-all cycles, delivery rate per oocyte retrieval was 21.39% for ICSI and 24.29% for IVF. Multiple births included 19.58% twins and 0.95% triplets and higher. In oocyte donation, delivery rate per transfer was 36.77%, with a twin and triplet rate of 27.65% and 1.06%, respectively. Overall, preterm deliveries reached 17.38% in singletons, 64.94% in twins and 98.41% in triplets. Perinatal mortality in 14,936 births and 18,391 babies born was 10.5 per 1000 in singletons, 17.9 per 1000 in twins, and 57.1 per 1000 in high-order multiples. Elective single embryo transfer represented 3.11% of fresh transfers, with a 31.78% delivery rate per transfer. Elective double embryo transfer represented 23.3% of transfers, with a 37.79% delivery rate per transfer. Out of 18,391 babies born, 63.22% were singletons, 34.4% twins, and 2.38% triplets and higher. Given the effect of multiple births on prematurity, morbidity and perinatal mortality, reinforcing the existing trend of reducing the number of embryos transferred remains mandatory.
- 1 January 2019
- Published by GN1 Sistemas e Publicacoes Ltd. in JBRA Assisted Reproduction
- Vol. 23 (2) , 143-153
Open AccessAssisted Reproductive Techniques in Latin America: The Latin American Registry, 2015
What was the utilization, effectiveness and safety of assisted reproductive technologies (ART) performed in Latin American countries during 2015, and what were the regional trends? Retrospective collection of multinational data on assisted reproduction techniques (IVF and intracytoplasmic sperm injection [ICSI], frozen embryo transfer, oocyte donation, preimplantation genetic testing and fertility preservation), from 175 institutions in 15 Latin American countries. In total, 41.25% of IVF/ICSI cycles were performed in women aged 35-39 years, and 28.35% in women aged ≥40 years. After removing freeze-all cycles, delivery rate per oocyte retrieval was 21.39% for ICSI and 24.29% for IVF. Multiple births included 19.58% twins and 0.95% triplets and higher. In oocyte donation, delivery rate per transfer was 36.77%, with a twin and triplet rate of 27.65% and 1.06%, respectively. Overall, preterm deliveries reached 17.38% in singletons, 64.94% in twins and 98.41% in triplets. Perinatal mortality in 14,936 births and 18,391 babies born was 10.5 per 1000 in singletons, 17.9 per 1000 in twins, and 57.1 per 1000 in high-order multiples. Elective single embryo transfer represented 3.11% of fresh transfers, with a 31.78% delivery rate per transfer. Elective double embryo transfer represented 23.3% of transfers, with a 37.79% delivery rate per transfer. Out of 18,391 babies born, 63.22% were singletons, 34.4% twins, and 2.38% triplets and higher. Given the effect of multiple births on prematurity, morbidity and perinatal mortality, reinforcing the existing trend of reducing the number of embryos transferred remains mandatory.
- 1 December 2018
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 37 (6) , 685-692
Assisted reproductive techniques in Latin America: the Latin American Registry, 2015
- 1 December 2018
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 37 (6) , 685-692
Assisted reproductive techniques in Latin America: the Latin American Registry, 2015
- Open Access
- 30 August 2017
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2017 (2) , hox013
Is there a reason to perform ICSI in the absence of male factor? Lessons from the Latin American Registry of ART
Does the use of ICSI offer any outcome advantage over IVF in patients with non-male factor infertility? We did not find any outcome improvement that justifies the routine use of ICSI over IVF in non-male factor ART cycles. Since its introduction in Latin America, the use of ICSI has increased substantially, even among patients without male factor infertility. However, it is not clear whether ICSI provides an advantage over IVF in non-male factor infertility. A retrospective cohort study of fresh cycles performed in 155 ART clinics located in 15 Latin American countries between 2012 and 2014. Records were assessed for 49,813 ART cycles (39,564 ICSI and 10,249 IVF) performed in infertile couples who did not have male factor infertility. Student’s t-test was used to analyze normally distributed data, Wilcoxon test to analyze non-normally distributed data, and Fisher’s exact test for categorical data. Logistic regression was used to quantify the effect of ICSI on delivery rate, adjusting for age of female partner, number of oocytes inseminated, number of embryos transferred, and transfer at blastocyst stage as possible confounding factors. Poisson regression analysis was used to quantify the effect of ICSI on fertilization rate, adjusting for age of female partner. Cycles with the diagnosis of male factor and use of cryopreserved semen and with a freeze-all strategy were excluded. After correcting for age of female partner, number of oocytes inseminated, number of embryos transferred and transfer at blastocyst stage, we found that the use of ICSI was associated with a significant decrease in the odds of delivery compared to IVF (odds ratio 0.88, 95% CI 0.84 to 0.93; P < 0.0001). An important limitation of this study is the lack of randomization owing to its retrospective nature. This could result in selection bias, i.e. couples with the worst prognosis undergoing ICSI, or patients with a history of fertilization failure in IVF cycles undergoing ICSI. More than one cycle from the same couple may be included in the study. The lack of an outcome benefit—and, indeed, a reduced likelihood of delivery—following ICSI in non-male factor infertile couples suggests that ICSI may not be the most appropriate clinical approach in these patients. None.
- 30 August 2017
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2017 (2) , hox013
Open AccessIs there a reason to perform ICSI in the absence of male factor? Lessons from the Latin American Registry of ART
Does the use of ICSI offer any outcome advantage over IVF in patients with non-male factor infertility? We did not find any outcome improvement that justifies the routine use of ICSI over IVF in non-male factor ART cycles. Since its introduction in Latin America, the use of ICSI has increased substantially, even among patients without male factor infertility. However, it is not clear whether ICSI provides an advantage over IVF in non-male factor infertility. A retrospective cohort study of fresh cycles performed in 155 ART clinics located in 15 Latin American countries between 2012 and 2014. Records were assessed for 49,813 ART cycles (39,564 ICSI and 10,249 IVF) performed in infertile couples who did not have male factor infertility. Student’s t-test was used to analyze normally distributed data, Wilcoxon test to analyze non-normally distributed data, and Fisher’s exact test for categorical data. Logistic regression was used to quantify the effect of ICSI on delivery rate, adjusting for age of female partner, number of oocytes inseminated, number of embryos transferred, and transfer at blastocyst stage as possible confounding factors. Poisson regression analysis was used to quantify the effect of ICSI on fertilization rate, adjusting for age of female partner. Cycles with the diagnosis of male factor and use of cryopreserved semen and with a freeze-all strategy were excluded. After correcting for age of female partner, number of oocytes inseminated, number of embryos transferred and transfer at blastocyst stage, we found that the use of ICSI was associated with a significant decrease in the odds of delivery compared to IVF (odds ratio 0.88, 95% CI 0.84 to 0.93; P < 0.0001). An important limitation of this study is the lack of randomization owing to its retrospective nature. This could result in selection bias, i.e. couples with the worst prognosis undergoing ICSI, or patients with a history of fertilization failure in IVF cycles undergoing ICSI. More than one cycle from the same couple may be included in the study. The lack of an outcome benefit—and, indeed, a reduced likelihood of delivery—following ICSI in non-male factor infertile couples suggests that ICSI may not be the most appropriate clinical approach in these patients. None.
- 21 June 2017
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 35 (3) , 287-295
Assisted reproduction techniques in Latin America: the Latin American Registry, 2014
- 21 June 2017
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 35 (3) , 287-295
Assisted reproduction techniques in Latin America: the Latin American Registry, 2014
- Open Access
- 24 January 2017
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 15 (1) , 8
The impact of endometriosis on the outcome of Assisted Reproductive Technology
Endometriosis has been described to impair fertility through various mechanisms. However, studies evaluating the reproductive outcomes of women undergoing assisted reproductive technologies show controversial results. The aim of this study is to assess whether the reproductive outcome is impaired among women with endometriosis-associated infertility undergoing IVF. A retrospective cohort study was performed, including women undergoing IVF reported by the Red Latinoamericana de Reproduccion Asistida (Redlara) registry, between January 2010 and December 2012. The study group included women with endometriosis-associated infertility, and the control group women with tubal factor, endocrine disorders or unexplained infertility. Women above 40 years, severe male factor and premature ovarian failure were excluded. The reproductive outcomes of between both groups were compared. The primary outcome was live birth. Secondary outcomes included clinical pregnancy, miscarriage, number of oocytes retrieved and number of fertilized oocytes. Outcomes were assessed after the first fresh IVF cycle, and were adjusted for age and number of embryos transferred. A total of 22.416 women were included (3.583 with endometriosis and 18.833 in the control group). Mean age of patients in the endometriosis group and control group was 34.86 (3.47) and 34.61 (3.91) respectively, p = 0.000. The mean number of oocytes retrieved were 8.89 (6.23) and 9.86 (7.02) respectively, p = 0.000. No significant differences were observed between groups in terms of live birth (odds ratio (OR) 1.032, p = 0.556), clinical pregnancy (OR 1.044, p = 0.428) and miscarriage rates (OR 1.049, p = 0.623). Women with endometriosis had significantly lower number of oocytes retrieved (incidence risk ratio (IRR) 0.917, 95% CI 0.895–0.940), however, the number of fertilized oocytes did not differ among the two groups when adjusting for the number of oocytes retrieved (IRR 1.003, p = 0.794). An age-stratified analysis was performed, and no differences were observed in the reproductive outcomes between groups for women aged under 35 and 35 to 40. Reproductive outcomes among women undergoing IVF and diagnosed with endometriosis-associated infertility do not differ significantly from women without the disease. Although women with endometriosis generate fewer oocytes, fertilization rate is not impaired and the likelihood of achieving a live birth is also not affected.
- 24 January 2017
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 15 (1) , 8
Open AccessThe impact of endometriosis on the outcome of Assisted Reproductive Technology
Endometriosis has been described to impair fertility through various mechanisms. However, studies evaluating the reproductive outcomes of women undergoing assisted reproductive technologies show controversial results. The aim of this study is to assess whether the reproductive outcome is impaired among women with endometriosis-associated infertility undergoing IVF. A retrospective cohort study was performed, including women undergoing IVF reported by the Red Latinoamericana de Reproduccion Asistida (Redlara) registry, between January 2010 and December 2012. The study group included women with endometriosis-associated infertility, and the control group women with tubal factor, endocrine disorders or unexplained infertility. Women above 40 years, severe male factor and premature ovarian failure were excluded. The reproductive outcomes of between both groups were compared. The primary outcome was live birth. Secondary outcomes included clinical pregnancy, miscarriage, number of oocytes retrieved and number of fertilized oocytes. Outcomes were assessed after the first fresh IVF cycle, and were adjusted for age and number of embryos transferred. A total of 22.416 women were included (3.583 with endometriosis and 18.833 in the control group). Mean age of patients in the endometriosis group and control group was 34.86 (3.47) and 34.61 (3.91) respectively, p = 0.000. The mean number of oocytes retrieved were 8.89 (6.23) and 9.86 (7.02) respectively, p = 0.000. No significant differences were observed between groups in terms of live birth (odds ratio (OR) 1.032, p = 0.556), clinical pregnancy (OR 1.044, p = 0.428) and miscarriage rates (OR 1.049, p = 0.623). Women with endometriosis had significantly lower number of oocytes retrieved (incidence risk ratio (IRR) 0.917, 95% CI 0.895–0.940), however, the number of fertilized oocytes did not differ among the two groups when adjusting for the number of oocytes retrieved (IRR 1.003, p = 0.794). An age-stratified analysis was performed, and no differences were observed in the reproductive outcomes between groups for women aged under 35 and 35 to 40. Reproductive outcomes among women undergoing IVF and diagnosed with endometriosis-associated infertility do not differ significantly from women without the disease. Although women with endometriosis generate fewer oocytes, fertilization rate is not impaired and the likelihood of achieving a live birth is also not affected.
- Open Access
- 1 January 2017
- Published by GN1 Sistemas e Publicacoes Ltd. in JBRA Assisted Reproduction
- Vol. 21 (1) , 19-22
Transfer of more than two embryos, regardless of the age of the female partner, is not beneficial for neither the mothers nor the babies: lessons from the Latin American Registry of Assisted Reproductive Techniques
Our findings suggest that eDET was associated with a statistically significant better delivery rate per embryo transfer, and lower ratio of triplet-and-higher deliveries, regardless of the woman's age. Therefore, there is no evidence that supports the transfer of more than two embryos.
- 1 January 2017
- Published by GN1 Sistemas e Publicacoes Ltd. in JBRA Assisted Reproduction
- Vol. 21 (1) , 19-22
Open AccessTransfer of more than two embryos, regardless of the age of the female partner, is not beneficial for neither the mothers nor the babies: lessons from the Latin American Registry of Assisted Reproductive Techniques
Our findings suggest that eDET was associated with a statistically significant better delivery rate per embryo transfer, and lower ratio of triplet-and-higher deliveries, regardless of the woman's age. Therefore, there is no evidence that supports the transfer of more than two embryos.
- 1 December 2016
- Published by Elsevier in Fertility and Sterility
- Vol. 106 (7) , 1714-1717.e1
Addition of neither recombinant nor urinary luteinizing hormone was associated with an improvement in the outcome of autologous in vitro fertilization/intracytoplasmatic sperm injection cycles under regular clinical settings: a multicenter observational analysis
- 1 December 2016
- Published by Elsevier in Fertility and Sterility
- Vol. 106 (7) , 1714-1717.e1
Addition of neither recombinant nor urinary luteinizing hormone was associated with an improvement in the outcome of autologous in vitro fertilization/intracytoplasmatic sperm injection cycles under regular clinical settings: a multicenter observational analysis
- 1 July 2015
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 31 (1) , 39-43
Effect of embryo freezing on perinatal outcome after assisted reproduction techniques: lessons from the Latin American Registry of Assisted Reproduction
- 1 July 2015
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 31 (1) , 39-43
Effect of embryo freezing on perinatal outcome after assisted reproduction techniques: lessons from the Latin American Registry of Assisted Reproduction